Related Experiment Video
Updated: Mar 10, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Microtubule actin cross-linking factor 1, a novel target in glioblastoma
Najlaa Afghani1, Toral Mehta1, Jialiang Wang2
1Department of Biological Sciences, Tennessee State University, Nashville, TN, USA.
Abstract:
Genetic heterogeneity is recognized as a major contributing factor of glioblastoma resistance to clinical treatment modalities and consequently low overall survival rates. This genetic diversity results in variations in protein expression, both intratumorally and between individual glioblastoma patients. In this regard, the spectraplakin protein, microtubule actin cross-linking factor 1 (MACF1), was examined in glioblastoma. An expression analysis of MACF1 in various types of brain tumor tissue revealed that MACF1 was predominately present in grade III-IV astroctyomas and grade IV glioblastoma, but not in normal brain tissue, normal human astrocytes and lower grade brain tumors. Subsequent genetic inhibition experiments showed that suppression of MACF1 selectively inhibited glioblastoma cell proliferation and migration in cell lines established from patient derived xenograft mouse models and immortalized glioblastoma cell lines that were associated with downregulation of the Wnt-signaling mediators, Axin1 and β-catenin. Additionally, concomitant MACF1 silencing with the chemotherapeutic agent temozolomide (TMZ) used for the clinical treatment of glioblastomas cooperatively reduced the proliferative capacity of glioblastoma cells. In conclusion, the present study represents the first investigation on the functional role of MACF1 in tumor cell biology, as well as demonstrates its potential as a unique biomarker that can be targeted synergistically with TMZ as part of a combinatorial therapeutic approach for the treatment of genetically multifarious glioblastomas.
Insights
Microtubule actin cross-linking factor 1 (MACF1) is upregulated in glioblastoma, promoting tumor growth. Inhibiting MACF1, alongside temozolomide (TMZ), offers a potential synergistic treatment strategy for glioblastoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Glioblastoma exhibits significant genetic heterogeneity, contributing to treatment resistance and poor survival rates.
- Variations in protein expression, including spectraplakin protein microtubule actin cross-linking factor 1 (MACF1), are observed within and between glioblastoma tumors.
- MACF1 expression is notably elevated in high-grade astrocytomas (grade III-IV) and glioblastoma (grade IV), but absent in normal brain tissue and lower-grade tumors.
Purpose of the Study:
- To investigate the functional role of MACF1 in glioblastoma cell biology.
- To determine if MACF1 can serve as a potential biomarker for glioblastoma.
- To explore the synergistic therapeutic potential of targeting MACF1 in combination with temozolomide (TMZ).
Main Methods:
- Expression analysis of MACF1 across various brain tumor grades and normal tissues.
- Genetic inhibition of MACF1 in patient-derived xenograft and immortalized glioblastoma cell lines.
- Assessment of MACF1 inhibition on glioblastoma cell proliferation and migration.
- Evaluation of combined MACF1 silencing and TMZ treatment on glioblastoma cell proliferation.
Main Results:
- MACF1 is predominantly expressed in high-grade astrocytomas and glioblastoma, distinguishing them from normal brain tissue and lower-grade tumors.
- Suppression of MACF1 selectively inhibited glioblastoma cell proliferation and migration.
- MACF1 inhibition led to the downregulation of Wnt-signaling mediators, Axin1 and β-catenin.
- Combined MACF1 silencing and TMZ treatment synergistically reduced glioblastoma cell proliferation.
Conclusions:
- MACF1 plays a significant role in glioblastoma tumor cell biology, influencing proliferation and migration.
- MACF1 is a potential diagnostic biomarker for high-grade gliomas.
- Targeting MACF1 synergistically with TMZ presents a promising combinatorial therapeutic strategy for glioblastoma.
Related Concept Videos
Destabilization of Microtubules
Microtubule Formation
Actin Filament Depolymerization
In F-actin, the ADF/cofilin proteins...
Microtubule Associated Proteins (MAPs)
Drugs that Stabilize Microtubules
Assembly of Complex Microtubule Structures

